A multicenter phase II randomized study of docetaxel (D)/gemcitabine (G) weekly followed by erlotinib (E) after progression versus erlotinib followed by docetaxel/gemcitabine after progression in advanced non-small cell lung cancer

被引：1

作者：

Le Caer, H.

Barlesi, F.

Corre, R.

Jullian, H.

Bota, S.

Falchero, L.

Vergnenegre, A.

Dujon, C.

Delhoume, J. Y.

Chouaid, C.

机构：

[1] CH Draguignan, Draguignan, France

[2] Univ Aix Marseille 2, Assistance Publ Hop Marseille, Marseille, France

[3] Rennes Univ Hosp, Rennes, France

[4] CH Martigues, Martigues, France

[5] Hop Charles Nicolle, CHU Rouen, Rouen, France

[6] CH Villefranche, Villefranche, France

[7] Univ Hosp, Limoges, France

[8] CH Versailles, Le Chesnay, France

[9] CH Perigueux, Perigueux, France

[10] Hop St Antoine, F-75571 Paris, France

来源：

关键词：

D O I：

10.1200/jco.2010.28.15_suppl.7536

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7536

引用

页数：1